Avantor Stock Price, News & Analysis

Avantor, Inc. (NYSE: AVTR) will release its financial results for the second quarter of 2022 post-market on July 28, 2022. A conference call is scheduled for July 29, 2022, at 8:00 a.m. EDT for further discussions. The earnings press release and presentation will be available on Avantor's website. As a leading global provider in life sciences and advanced technologies, Avantor serves over 225,000 customer locations across more than 180 countries, highlighting its significant market presence. Investors are encouraged to tune in for insights into the company's performance.

Avantor (NYSE: AVTR) has announced a collaboration with GeminiBio to deliver custom hydrated solutions and cell culture media tailored for the biopharma industry. This partnership aims to enhance bioproduction workflows, particularly for emerging modalities like gene therapy, enabling faster product development from research through to commercialization. Avantor's strategic investments and acquisitions complement this initiative, demonstrating its commitment to optimizing customer processes and improving efficiency in biomanufacturing.

Avantor (NYSE: AVTR), a global leader in mission-critical products and services, announced that its President and CEO, Michael Stubblefield, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at 11:00 a.m. EDT. The event will take place in Rancho Palos Verde, California. Interested parties can access a live webcast on the company's investor section of their website, with a replay available for 90 days. Avantor serves over 225,000 customers across various industries, emphasizing innovation in life sciences and advanced technologies.

Avantor, Inc. (NYSE: AVTR) announced the automatic conversion of its 6.250% Series A Mandatory Convertible Preferred Stock into common stock on May 16, 2022. Each share of Preferred Stock will convert into 3.0395 shares of common stock, with cash paid for any fractional shares. Holders of record as of May 1, 2022 will also receive a final quarterly cash dividend of $0.78 per share payable on the conversion date.

Avantor, Inc. (NYSE: AVTR) has elected Jonathan Peacock, 64, as the new chairman of its board of directors, effective after the annual stockholder meeting today. Peacock succeeds Raj Gupta, who is retiring. Peacock, a board member since 2017, highlighted the company's potential for growth and scientific breakthroughs. He has extensive experience, having held leadership roles at Amgen and Novartis. Avantor is a global provider of mission-critical products and services for life sciences and advanced technologies, serving over 225,000 customers in more than 180 countries.

Avantor (NYSE: AVTR) has partnered with Cytovance Biologics to enhance plasmid DNA development for biopharma clients. This collaboration will leverage Cytovance's cGMP manufacturing capabilities, significantly boosting Avantor's offerings in the rapidly growing gene therapy sector. As demand for therapeutic biologics rises, this partnership is positioned to support increased manufacturing capacity and meet the needs of emerging mRNA and viral vector therapies. Both companies aim to expand their global reach and provide critical materials for research and commercialization.

Avantor, Inc. (NYSE: AVTR) announced on May 5, 2022, the establishment of a new manufacturing and distribution hub in Singapore. This hub aims to enhance supply chain capabilities and better serve the burgeoning Asia Pacific Biopharma market. Integrating existing facilities with new manufacturing operations, the hub will boost regional innovation and deliver services such as quality control and testing labs, becoming operational early next year. This strategic move highlights Avantor's commitment to expanding in Asia and improving lead times and supply chain security.

Avantor reported financial results for Q1 2022, highlighting net sales of $1.95 billion, a 9.2% increase year-over-year. The company achieved organic net sales growth of 5.1% and net income of $190.4 million, up from $164 million in Q1 2021. Adjusted EBITDA rose 16.5% to $423.1 million, with an Adjusted EBITDA margin of 21.7%. Operating cash flow was $152.2 million and free cash flow was $127.7 million. The company also reduced adjusted net leverage to 4.0X, aligning with its long-term target.